Molecular Partners AG (XSWX:MOLN) Total Liabilities : CHF21.92 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Total Liabilities?

Molecular Partners AG's Total Liabilities for the quarter that ended in Dec. 2023 was CHF21.92 Mil.

Molecular Partners AG's quarterly Total Liabilities declined from Jun. 2023 (CHF24.52 Mil) to Sep. 2023 (CHF21.91 Mil) but then increased from Sep. 2023 (CHF21.91 Mil) to Dec. 2023 (CHF21.92 Mil).

Molecular Partners AG's annual Total Liabilities declined from Dec. 2021 (CHF65.38 Mil) to Dec. 2022 (CHF27.09 Mil) and declined from Dec. 2022 (CHF27.09 Mil) to Dec. 2023 (CHF21.92 Mil).

Molecular Partners AG Total Liabilities Historical Data

The historical data trend for Molecular Partners AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Total Liabilities Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

50.80

80.33

65.38

27.09

21.92

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															27.09	22.37	24.52	21.91	21.92

Molecular Partners AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Molecular Partners AG's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.416	+	(2.444	+	-1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	5.063)
	=	21.92

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	198.352	-	176.429
	=	21.92

Molecular Partners AG's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.416	+	(2.444	+	-1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	5.063)
	=	21.92

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	198.352	-	176.429
	=	21.92

Molecular Partners AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.